Chang Gong
Heath Park
Cardiff, WLS, United Kingdom
Cardiff, WLS, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: March 19, 2026
3D-printed cell-free bioactive scaffolds from methacrylated hyaluronic acid and silk fibroin incorporating platelet-rich plasma for adipose tissue regeneration.
Journal: International journal of biological macromolecules
Published: December 03, 2025
Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: September 11, 2025
Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis.
Journal: The Journal of clinical investigation
Published: August 21, 2025
Development and validation of a clinical-bimodal nomogram to predict the malignancy of pathologic nipple discharge.
Journal: Quantitative imaging in medicine and surgery
Published: March 19, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.
Journal: Nature communications
Published: October 11, 2024
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial.
Journal: BMC medicine
Published: September 03, 2024
Simeprevir induces ferroptosis through β-TrCP/Nrf2/GPX4 axis in triple-negative breast cancer cells.
Simeprevir induces ferroptosis through β-TrCP/Nrf2/GPX4 axis in triple-negative breast cancer cells.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 04, 2024
Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy.
Journal: Nature communications
Published: June 24, 2024
Expression of Concern: Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 14, 2024
Last Updated: 09/26/2026